Keytruda, a blockbuster immunotherapy used to treat various cancers, generated global sales of $29.5 billion in 2024. The collaboration aims to leverage the biosimilar strengths of both companies, accelerating development timelines and expanding the product’s international reach.
Under the agreement, Dr. Reddy’s and Alvotech will jointly manage development, production, and commercialisation, sharing responsibilities and costs. Except in certain cases, both firms will also have rights to market the biosimilar in global markets.
Also Read: MRF snatches India’s highest-priced stock crown back from Elcid Investments
Dr Reddy’s Laboratories Q4 earnings
Dr. Reddy’s reported a 22% year-on-year increase in consolidated net profit to Rs 1,594 crore for the January–March quarter of FY25, compared to Rs 1,307 crore in the same period last year.
Revenue from operations rose 20% year-on-year to Rs 8,506 crore, up from Rs 7,083 crore in Q4FY24. On a sequential basis, revenue was up 1.8% from Rs 8,359 crore in the October–December quarter.Quarter-on-quarter, profit after tax grew 13% from Rs 1,413 crore in Q3FY25. All profits were attributable to equity shareholders of the company.Also Read: India’s top 10 priciest stocks in 2025: MRF to Elcid, see who tops the list
Dr Reddy’s Laboratories shares price target
According to Trendlyne data, the average target price for Dr. Reddy’s shares stands at Rs 1,271, implying a potential downside of around 1% from current levels. Out of 38 analysts tracking the stock, the consensus rating is ‘Hold’.
So far in 2025, the stock is down 6% year-to-date, though it has gained 14% over the past three months. Dr. Reddy’s Laboratories currently has a market capitalisation of Rs 1,07,310 crore.
Also Read: Ola Electric, Kalyan Jewellers among 10 firms where promoters pledge increased in Q4
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
By
